Major vascular surgery is frequently associated with significant blood loss and coagulopathy. Existing evidence suggests hypofibrinogenaemia develops earlier than other haemostatic deficiencies during major blood loss. The purpose of this study was to assess whether the use of an infusion of fibrinogen concentrate to prevent and treat hypofibrinogenaemia during surgery resulted in satisfactory haemostasis, removing or reducing the need for blood component transfusion. Twenty patients undergoing elective extent-4 thoraco-abdominal aortic aneurysm repair were randomly allocated to receive either fresh frozen plasma or fibrinogen concentrate to treat hypofibrinogenaemia during surgery. Coagulation was assessed during and after surgery by point-of-care and laboratory testing, respectively, and treatment was guided by pre-defined transfusion triggers. Despite blood losses of up to 11,800 ml in the patients who received the fibrinogen concentrate, none required fresh frozen plasma during surgery, and only two required platelet transfusions. The median (IQR [range]) allogeneic blood component administration during surgery and in the first 24 h postoperatively was 22.5 (14-28 [2-41]) units in patients allocated to fresh frozen plasma vs. 4.5 (3-11[0-17]) in patients allocated to fibrinogen concentrate (p = 0.011). All patients in both groups were assessed by the surgeon to have satisfactory haemostasis at the end of surgery. Mean (SD) postoperative fibrinogen concentrations were similar in patients allocated to fresh frozen plasma and fibrinogen concentrate (1.6 (0.3) g.l À1 vs. 1.6 (0.2) g.l À1 ; p = 0.36) but the mean (SD) international normalised ratio and activated partial thromboplastin time ratio were lower in patients allocated to fresh frozen plasma (1.1 (0.1) vs.
Introduction
Open thoraco-abdominal aortic aneurysm repair is associated with major haemorrhage and the development of coagulopathy during surgery [1] . Causes of coagulopathy include haemodilution and abdominal visceral ischaemia leading to deficiencies of fibrinogen and other coagulation factors, thrombocytopenia and excessive fibrinolysis. The intra-operative administration of heparin and pre-operative antiplatelet drugs may also impair haemostasis. Impairment of haemostasis is commonly treated with the transfusion of fresh frozen plasma (FFP), cyoprecipitate and platelet concentrates [2] . However, blood component transfusions may result in adverse effects including the transmission of infection, immunosuppression and lung injury [3] . Furthermore, delays in obtaining blood components may occur because FFP and cryoprecipitate must be thawed before administration and platelet concentrates, which have a shelf life of only a few days [4] , are sometimes in short supply and, in some hospitals, not immediately available on-site.
After massive haemorrhage and haemodilution, a deficiency of fibrinogen is likely to result in impaired haemostasis before thrombocytopenia or deficiencies of other coagulation factors become severe enough to do so [5] [6] [7] . In addition, fibrin polymerisation may be impaired by haemodilution, particularly when synthetic colloids are administered [8] . Fibrinogen may be replaced by transfusing FFP or cryoprecipitate but an alternative is to give fibrinogen concentrate. Fibrinogen concentrate is derived from pooled human plasma which is purified, treated to inactivate pathogens and freeze dried. It may be stored at room temperature in the operating room and then dissolved in sterile water when required. Data exist supporting its safety [9, 10] and it is thought to be associated with a lower risk of adverse effects when compared with blood components [11] .
A standard adult therapeutic dose of cryoprecipitate (two pools) is produced from 10 donors, contains around 3.3 g of fibrinogen and has a volume of approximately 380 ml [4] . A standard adult therapeutic dose of FFP (four units) is from four donors, typically contains 2.8 g of fibrinogen and has a larger volume of approximately 1070 ml [12, 13] . Fibrinogen concentrate is supplied as 1 g fibrinogen to be prepared in 50 ml of sterile water.
We hypothesised that the principal deficiency resulting in impaired haemostasis during thoraco-abdominal aortic aneurysm surgery is fibrinogen deficiency and that maintaining the plasma fibrinogen concentration within the normal range by infusion of fibrinogen concentrate would result in satisfactory haemostasis while avoiding or reducing the need for blood component transfusion to correct haemostasis.
In a single-blind pilot, we compared the use of our Intravenous unfractionated heparin (70 iU.kg
À1
) was given before aortic clamping and was not reversed. 
Results
Twenty-three patients were assessed for enrolment in the study of whom 20 completed the study (10 in each group) (Fig. 1) . Baseline characteristics of participants are shown in Table 2 . In each group, nine patients were taking aspirin and this was not omitted before surgery.
One patient allocated to FFP was taking dipyridamole in addition to the aspirin, but this was discontinued 5 days Intra-operative blood loss and fluid administration volumes are shown in Table 3 , with intra-operative blood component and fibrinogen concentrate administration shown in Fig. 2 and Table 4 . No FFP was given to the 10 patients allocated to fibrinogen concentrate during surgery.
Only two patients allocated to fibrinogen concentrate, with intra-operative blood losses of 9725 ml and 11,800 ml received platelet transfusions during surgery. All patients in both groups were assessed by the surgeon to have satisfactory haemostasis at the end of surgery.
After the end of surgery, but while the patient was still in the operating theatre, one of the patients allocated to fibrinogen concentrate developed signs suggestive of haemorrhage. The abdomen was re-opened and bleeding from a small artery was found requiring surgical correction.
On closing the abdomen at the end of the initial operation (total estimated blood loss 7900 ml), the surgeon had Table 5 . Three patients allocated to fibrinogen concentrate (including the patient described above) received FFP in the critical care unit postoperatively because the APTTr was > 2.0 despite a laboratory fibrinogen concentration in the normal range (intraoperative blood losses 9725 ml, 11,800 ml and 12,200 ml).
There were no clinical signs of bleeding in these three patients and each patient received either one or two units of FFP which is less than a standard adult dose. Our protocol specified that FFP should be given if the APTTr was > 2.0 but not how much should be given. In the absence of clinical signs of bleeding, the clinicians looking after the patients in critical care elected to give only one or two units of FFP.
Three patients in the fibrinogen group, all with intraoperative blood losses > 9000 ml, received platelets in the first 24 h after surgery. .l À1 , respectively; p = 0.39). Postoperative complications and duration of stay in critical care and hospital were similar in both groups (Table 6 ).
Discussion
We used fibrinogen concentrate as an alternative to FFP in the treatment of acquired hypofibrinogenaemia during major vascular surgery. All patients who received fibrinogen concentrate had satisfactory clotting at the end of surgery as assessed by point-of-care testing. Patients who received fibrinogen concentrate and who had a measured blood loss during surgery of up to 8800 ml did not receive any blood component transfusion apart from red cells during surgery or in the first 24 h after surgery.
As this is a pilot study involving a small number of patients, caution should be exercised in the interpretation of these findings. However, our results suggest that when fibrinogen concentrate is given it may be feasible to avoid the transfusion of haemostatic blood components (FFP, cryoprecipitate and platelets) during and after elective major vascular surgery with intra-operative blood loss of up to 9000 ml.
Previous retrospective studies have compared the administration of fibrinogen concentrate and prothrombin complex concentrate (PCC) with the administration of FFP in cardiac surgery [16] and trauma [17] . However, we believe this to be the first study in which an infusion of fibrinogen during surgery has been used to prevent or correct hypofibrinogenaemia.
We maintained or corrected plasma fibrinogen concentration to around 1.5 g.l 6] 4100, [11.8] 5000, [8] 6282, [6] 7900, [10] 8809, [8] 9097, [9.3] 9725, [10] 11800, [17.5] No ) did not reduce blood loss or transfusion requirements [20] .
Similarly, in a study of patients having high-risk cardiac surgery who were bleeding after the end of bypass and had a mean fibrinogen concentration of 1.7 g.l
À1
, the administration of fibrinogen concentrate did not reduce subsequent intra-operative blood loss [21] . A study of patients with postpartum haemorrhage concluded that fibrinogen replacement is not required if the plasma fibrinogen concentration is > 2 g.l
, but a beneficial effect below that level could not be excluded [22] . On the other hand, a study of fibrinogen concentrate administration after complex cardiac surgery to patients with risk factors for transfusion whose fibrinogen concentrations appear, in most cases, to have been > 1.5 g.l À1 resulted in a reduction in blood component transfusion and postoperative bleeding [23, 24] . The same group, after a larger but retrospective study [25] , proposed 1.15 g.l À1 as a trigger value for fibrinogen supplementation after cardiac surgery with a post-treatment target value of 2.80 g.l
. In actively bleeding patients, these values were increased to 2.15 g.l Patients who received fibrinogen concentrate during surgery; n -9 PRC, packed red cells. Table 5 Total number of blood components administered to patients randomly allocated to receive either fresh frozen plasma (FFP) or fibrinogen concentrate during thoracoabdominal aortic aneurysm surgery in the first 24 h after surgery. The components transfused when a patient was re-opened in the operating room due to arterial bleeding are not included here but are described in the text. major haemorrhage in surgery [5] , obstetrics [28] and trauma [29] , low fibrinogen concentration is usually the first deficiency to result in impaired haemostasis, and hypofibrinogenaemia may itself lead to a prolonged INR and APTTr since the end-point of these tests is the formation of fibrin. A standard adult therapeutic dose of FFP contains approximately 2.8 g of fibrinogen [12, 13] . Therefore, it may well be that the principal benefit of FFP administration to these patients is the correction of hypofibrinogenaemia.
Although fibrinogen concentrate has usually been considered to be an alternative to the use of cryoprecipitate in bleeding surgical, obstetric and trauma patients, we suggest that it should also be considered an alternative to FFP. [31] . Current guidelines on the management of bleeding surgical, trauma and obstetric patients [27, 32, 33] recommend maintaining a fibrinogen concentration of .
There are some limitations to our study. First, this was a pilot study that was not powered to detect differences in clinical outcomes. Second, the clinicians caring for the patients were not blinded to the treatment group.
However, the decision as to whether to administer a blood component transfusion was made on the basis of pre-defined ROTEM and laboratory test transfusion triggers and it is unlikely that blinding would have resulted in additional transfusions. Third, large volumes of synthetic colloid fluids were given to both groups as was our routine practice at the time of the study, and this may have impaired coagulation [7, 8] . Our current practice is to use predominantly crystalloid fluids with a much lower volume of colloids and it is possible that with this approach the impairment of haemostasis and need for haemostatic blood component transfusions may be further reduced.
This study suggests that fibrinogen concentrate may be given instead of FFP to treat coagulopathy during complex vascular surgery and that its use results in reduced allogeneic blood component transfusion. A larger study is required to establish whether the administration of fibrinogen concentrate rather than FFP during surgery leads to a difference in clinical outcomes.
